Pancreas Transplant in India and UAE | Complete Patient Guide

• IDEAL CANDIDATES:

• Type 1 diabetes mellitus with absolute insulin deficiency confirmed by low fasting C-peptide levels (<0.3 ng/mL)

• Brittle (labile) diabetes with recurrent, severe hypoglycemia or hypoglycemic unawareness unresponsive to optimal medical management including continuous glucose monitors and closed-loop insulin pump systems

• Diabetic nephropathy with eGFR <20 mL/min/1.73m² (SPK) or functioning renal allograft (PAK)

• Type 1 diabetes without renal failure but with life-threatening metabolic instability (PTA)

• Post-total pancreatectomy patients requiring islet autotransplantation (IAT) or whole-organ allograft

• Patients aged 18–55 years (relative; selected centers accept up to 60 years with individualized assessment)

• REQUIRED PRE-TRANSPLANT DIAGNOSTICS:

• Comprehensive metabolic panel, HbA1c, fasting C-peptide, auto-antibodies (GAD65, IA-2, ZnT8)

• ABO blood group and HLA tissue typing; Panel Reactive Antibody (PRA) testing; crossmatch

• 2D Echocardiogram (ECHO) and stress testing (dobutamine stress ECHO or nuclear perfusion scan) to exclude occult coronary artery disease

• Cardiac catheterization if stress test is positive or equivocal

• Renal function panel: 24-hour urine protein, eGFR, renal ultrasound; nuclear GFR if borderline

• CT angiography of the abdomen and pelvis to assess iliac vessel anatomy for graft implantation planning

• Chest X-ray, pulmonary function tests, and infectious disease serology (CMV, EBV, HIV, Hepatitis B/C, TB QuantiFERON)

• Colonoscopy (if age >50 or symptomatic), dental and ophthalmology clearance

• Psychosocial evaluation and confirmation of medication adherence capacity

• ABSOLUTE CONTRAINDICATIONS:

• Active malignancy or remission <2–5 years (tumor-type dependent)

• Active systemic infection or untreated sepsis

• Severe irreversible cardiac disease (ejection fraction <25%) or unrevascularizable coronary artery disease

• Severe peripheral vascular disease precluding safe iliac anastomosis

• Active substance abuse or inability to commit to lifelong immunosuppression

• Morbid obesity (BMI >35) at most centers (relative contraindication; assessed individually)

• Severe pulmonary hypertension or advanced hepatic cirrhosis

• Active psychiatric illness that precludes informed consent or post-transplant adherence

SIMULTANEOUS PANCREAS-KIDNEY (SPK) TRANSPLANT — STANDARD APPROACH: The SPK procedure is performed under general anesthesia via a midline or bilateral lower-quadrant laparotomy. The pancreatic allograft (procured with the duodenal segment intact) is implanted in the right iliac fossa with arterial reconstruction using a donor Y-graft (iliac artery bifurcation) anastomosed end-to-side to the recipient right common or external iliac artery. Venous drainage is achieved via end-to-side anastomosis to the right common iliac vein (systemic drainage) or, at select centers using the portal-enteric drainage technique, to the superior mesenteric vein for more physiological insulin delivery directly into the portal circulation. Exocrine secretions are drained via a duodeno-jejunostomy (enteric drainage)—now the preferred technique globally—avoiding the metabolic complications of the older bladder-drainage method. The renal allograft is implanted separately in the left iliac fossa using standard techniques. Total operative time is typically 4–6 hours.

PANCREAS AFTER KIDNEY (PAK) AND PANCREAS TRANSPLANT ALONE (PTA): These are technically similar to the SPK pancreas implantation but performed as single-organ procedures. PTA candidates must meet stringent metabolic criteria, and careful risk-benefit analysis is essential given the immunosuppression burden without the concomitant renal benefit.

MINIMALLY INVASIVE AND ROBOTIC-ASSISTED APPROACHES: A small number of high-volume academic centers have begun performing robotic-assisted pancreas transplantation using the da Vinci Xi surgical system. This technique involves 4–5 port placements and uses intracorporeal vascular anastomosis. Reported advantages include reduced wound complications (particularly in obese patients), lower incidence of incisional hernia, and shorter hospital stay. While not yet the global standard, robotic pancreas transplantation represents the most advanced frontier of the procedure and is available at select centers partnered with GAF Healthcare.

ISOLATED ISLET CELL TRANSPLANTATION (EDMONTON PROTOCOL): For selected PTA candidates—particularly those with prohibitive surgical risk—intraportal infusion of purified islet cells (700,000–1,000,000 islet equivalents) from one or two donors can restore partial or complete insulin independence. The Edmonton Protocol, refined with anti-inflammatory induction (etanercept, exenatide) and steroid-free immunosuppression, achieves insulin independence in approximately 50–60% of patients at 5 years. Islet transplantation is performed as a minimally invasive percutaneous transhepatic procedure under fluoroscopic guidance and does not require general anesthesia or major surgery. However, it requires an approved islet processing facility and is offered at specialized centers.

TOTAL PANCREATECTOMY WITH ISLET AUTOTRANSPLANTATION (TP-IAT): For patients with chronic pancreatitis, TP-IAT removes the diseased pancreas, isolates the patient's own islet cells in a sterile processing laboratory, and reinfuses them into the portal vein intraoperatively. Because autologous cells are used, immunosuppression is not required. Insulin independence is achieved in approximately 30–40% of patients; partial function (reducing insulin requirements) is achieved in a further 30–40%.

IMMUNOSUPPRESSION PROTOCOLS AND REJECTION MANAGEMENT: Induction: ATG (anti-thymocyte globulin, e.g., Thymoglobulin) or IL-2 receptor antagonist (basiliximab) at the time of transplant. Maintenance: Tacrolimus (target trough 8–12 ng/mL in early months, weaned to 5–8 ng/mL), Mycophenolate Mofetil (1–1.5 g twice daily), and prednisolone (tapering from 20 mg/day to 5 mg/day over 3–6 months; steroid-free protocols considered after 1 year). Acute rejection is treated with pulse methylprednisolone; antibody-mediated rejection (AMR) with plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab (anti-CD20 monoclonal antibody).

PHASE 1 — REMOTE EVALUATION (Weeks 1–3 before travel): Patients submit medical records, recent labs, imaging, and cardiac evaluation results to the GAF Healthcare clinical coordination team. A senior transplant nephrologist and pancreatic transplant surgeon review the case remotely. Virtual consultation is scheduled to confirm candidacy, discuss procedure type (SPK/PAK/PTA), review waitlist logistics (deceased donor) or living-related evaluation, and issue a detailed cost estimate and preliminary treatment plan.

PHASE 2 — ARRIVAL AND PRE-TRANSPLANT WORKUP (Days 1–7 in country): Upon arrival, the patient undergoes a structured inpatient or outpatient pre-transplant evaluation: repeat HLA crossmatch with the identified deceased donor (if transplant is imminent), repeat ECHO, CT angiography review, infectious serology confirmation, and anesthesia fitness assessment. Immunosuppression induction medications are initiated. For deceased-donor transplants, patients may be placed on an active waitlist at the center and must remain in-country. Living-donor pancreas transplantation (rare; partial graft from living donor) is evaluated separately.

PHASE 3 — SURGERY DAY (Day 0): On receipt of a suitable donor organ (cold ischemia time <12 hours is prioritized), the patient proceeds to the operating theater. General anesthesia is induced. The surgical team performs vascular and enteric anastomoses as described above. Intraoperative graft perfusion is confirmed by Doppler ultrasound on the table. Intraoperative blood glucose normalization—typically within 1–2 hours of pancreatic reperfusion—confirms immediate graft function. Operative duration: 4–6 hours (SPK: 5–8 hours).

PHASE 4 — INTENSIVE CARE UNIT (Days 1–3 post-op): Patient is monitored in the ICU or high-dependency unit. Hourly blood glucose monitoring; target range 70–140 mg/dL without exogenous insulin indicates primary graft function. Serum amylase, lipase, creatinine (for SPK), and urine output are tracked. IV tacrolimus or oral tacrolimus is initiated. Doppler ultrasound of graft vessels performed on Day 1 to exclude vascular thrombosis—the most feared early complication.

PHASE 5 — WARD RECOVERY (Days 4–14): Progressive ambulation from Day 3 onward. Oral diet re-introduced from Day 3–5 following confirmation of bowel function (enteric drainage). Oral immunosuppression fully established. Twice-daily blood glucose monitoring continues; exogenous insulin is withheld if glucose remains <140 mg/dL. Serum tacrolimus trough levels monitored every 2–3 days and dose adjusted. Rejection surveillance with clinical parameters and labs; graft biopsy if amylase/lipase spikes or unexplained hyperglycemia occurs.

PHASE 6 — PRE-DISCHARGE EDUCATION (Days 14–21): Patient and caregiver are comprehensively trained in: daily blood glucose and blood pressure monitoring; immunosuppression schedule and medication storage; signs of rejection (fever, graft tenderness, rising glucose, rising creatinine for SPK); infection prophylaxis protocols (trimethoprim-sulfamethoxazole for PCP, valganciclovir for CMV, fluconazole for fungal prophylaxis). Discharge planning and outpatient follow-up schedule established.

PHASE 7 — POST-DISCHARGE OUTPATIENT FOLLOW-UP IN COUNTRY (Weeks 3–6): Weekly outpatient clinic visits for labs: tacrolimus trough, CBC, comprehensive metabolic panel, fasting glucose, HbA1c at Week 6, C-peptide. Any rejection episode or surgical complication is managed during this critical window. Physical activity is gradually increased; driving and heavy lifting are restricted for 6–8 weeks.

FIT-TO-FLY MILESTONE (Weeks 6–10): Clearance for international air travel requires: stable graft function (fasting glucose <126 mg/dL without insulin, stable tacrolimus troughs), absence of active infection or rejection, wound fully healed, and surgeon sign-off. GAF Healthcare coordinates a summary medical report and adequate immunosuppression medication supply (minimum 3-month supply) for the return journey. Patients are connected with a transplant center in their home country for ongoing immunosuppression monitoring.